Intraocular Melanoma Clinical Trial
Official title:
A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle
formulation works in treating patients with metastatic melanoma of the eye that cannot be
removed by surgery.
Status | Completed |
Enrollment | 4 |
Est. completion date | April 2013 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed evidence of metastatic/ unresectable uveal melanoma - Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension and is =10 mm by spiral CT scan - 18 years or older - Eastern Cooperative Oncology Group(ECOG)performance status 0, or 1 - No known HIV or Hepatitis B or C - Patients with brain metastasis are eligible for entry into the study - Patients must have normal organ/marrow function as defined below: - Absolute neutrophil count = 1.5 x 109/L - Platelets = 100,000 x 109/L - Hemoglobin = 9.0 gm/100 ml - Total bilirubin = 1.5. In patients with Gilbert's disease the indirect bilirubin must be less than or equal to 4.0. - AST and ALT = 2.5x upper limit of normal - Alkaline phosphatase = 2.5x upper limit of normal, unless bone metastases is present in the absence of liver metastasis - Creatinine = 1.8 mg/ml or calculated creatinine clearance > 50 mg ml. - Calcium <12 mg/dl when corrected for levels of serum albumen - Patients my have had up to one prior systemic therapy Exclusion Criteria: - Chemotherapy or radiotherapy within 4 weeks prior to entering the study or failure to recover from adverse events due to agents administered more than 4 weeks earlier. - May not be receiving any other simultaneous investigational agents - No prior malignancy except for adequately treated basal cell cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years. - Patients who have serious infections or other major uncontrolled medical illnesses. - Patients who have significant psychiatric illness who in the opinion of the principal investigator would prevent adequate informed consent or render therapy unsafe. - Patients who are pregnant. Female patients of child bearing potential must have a negative serum pregnancy test and use adequate contraception protection while on study. - Peripheral neuropathy of > grade 2. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center | Celgene Corporation, National Comprehensive Cancer Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | up to 1 year following last treatment, for a total of approximately 5 years | No |
Secondary | Progression-free Survival | Median progression free survival (PFS) in patients with metastatic uveal melanoma who received nab-paclitaxel | up to 1 year following last treatment, for a total of approximately 5 years | No |
Secondary | Overall Survival | Overall Survival is defined as the time from the start of treatment (study day 1) until death to the date of his or her death. If the subject has not died, survival time will be censored on last date the subject was known to be alive. | up to 1 year following last treatment, for a total of approximately 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01217398 -
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Completed |
NCT00471471 -
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 1 | |
Completed |
NCT00398073 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
N/A | |
Completed |
NCT00334776 -
Vaccine Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00025181 -
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
|
Phase 1 | |
Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00897624 -
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
|
N/A | |
Completed |
NCT00003339 -
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00084656 -
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00705640 -
Vaccine Therapy in Treating Patients With Advanced Melanoma
|
Phase 1 | |
Recruiting |
NCT00489944 -
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
|
Phase 2 | |
Completed |
NCT00027742 -
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00952939 -
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
|
N/A | |
Terminated |
NCT00005841 -
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00089219 -
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00072345 -
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00445965 -
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
|
Phase 2 | |
Completed |
NCT00243061 -
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT00110123 -
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
|
Phase 3 | |
Completed |
NCT00032045 -
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 |